European Archives of Oto-Rhino-Laryngology

, Volume 270, Issue 7, pp 1999–2006 | Cite as

The evaluation of ozone and betahistine in the treatment of tinnitus

  • Onur Sönmez
  • İsmail Külahlı
  • Alperen Vural
  • Mehmet İlhan Şahin
  • Mesut Aydın


The aim of the study is to evaluate the effectiveness of ozone and betahistine treatments in the treatment of tinnitus. Sixty-eight patients were enrolled in this randomized, prospective controlled study. The ozone group consisted of 27, betahistine group consisted of 26 and control group consisted of 15 patients. The patients in ozone group received 10 sessions of ozone treatment via major autohemotherapy. Betahistine group received 48 mg/day betahistine tablets per oral for 3 months duration. The control group was followed up without any treatment given. The evaluation of tinnitus was made by tinnitus loudness and tinnitus handicap inventory (THI). The changes in findings from baseline to 3rd and 6th months were assessed, and the group results were compared. Comparison of the initial mean tinnitus loudness and 3 and 6 months after treatment in each of the three groups did not reveal a significant difference. The comparison between the groups in terms of the improvement of tinnitus loudness was not significant (p = 0.821). Comparison of the initial mean THI and 3 and 6 months after treatment revealed a significant difference in ozone and betahistine groups but not in the control group. When the delta (Δ) THI (the change of mean THI between the initial and 6th month) was compared between the groups, there was no significant difference. This randomized controlled study investigating the effects of ozone in tinnitus tries to shed light to a new method of treatment in tinnitus. The findings of the study does not provide enough evidence to support ozone and betahistine as a treatment for tinnitus and further research on the subject is necessary.


Tinnitus Ozone Betahistine 



This study is funded by Erciyes University Scientific Research Supporting Fund.


  1. 1.
    Eggermont JJ (2003) Central tinnitus. Auris Nasus Larynx 30:7–12CrossRefGoogle Scholar
  2. 2.
    Jastreboff PJ, Jastreboff MM (2000) Tinnitus Retraining Therapy (TRT) as a method for treatment of tinnitus and hyperacusis patients. J Am Acad Audiol 11(3):162–177PubMedGoogle Scholar
  3. 3.
    Axelsson A, Ringdahl A (1989) Tinnitus—a study of its prevalence and characteristics. Br J Audiol 23(1):53–62. doi:10.3109/03005368909077819 PubMedCrossRefGoogle Scholar
  4. 4.
    Megwalu UC, Finnell JE, Piccirillo JF (2006) The effects of melatonin on tinnitus and sleep. Otolaryngol Head Neck Surg 134(2):210–213. doi:10.1016/j.otohns.2005.10.007 PubMedCrossRefGoogle Scholar
  5. 5.
    Canis M, Olzowy B, Welz C, Suckfull M, Stelter K (2011) Simvastatin and Ginkgo biloba in the treatment of subacute tinnitus: a retrospective study of 94 patients. Am J Otolaryngol 32(1):19–23. doi:10.1016/j.amjoto.2009.09.004 PubMedCrossRefGoogle Scholar
  6. 6.
    Miller JM, Ren TY, Nuttall AL (1995) Studies of inner ear blood flow in animals and human beings. Otolaryngol Head Neck Surg 112(1):101–113. doi:10.1016/S0194-5998(95)70308-X PubMedCrossRefGoogle Scholar
  7. 7.
    Baguley DM (2002) Mechanisms of tinnitus. Br Med Bull 63:195–212PubMedCrossRefGoogle Scholar
  8. 8.
    Jastreboff PJ (1990) Phantom auditory perception (tinnitus): mechanisms of generation and perception. Neurosci Res 8(4):221–254PubMedCrossRefGoogle Scholar
  9. 9.
    Moller AR (2003) Pathophysiology of tinnitus. Otolaryngol Clin North Am 36 (2):249–266, v–viGoogle Scholar
  10. 10.
    Kaltenbach JA (2000) Neurophysiologic mechanisms of tinnitus. J Am Acad Audiol 11(3):125–137PubMedGoogle Scholar
  11. 11.
    Antonio P, Borghi C, Ferri GG (2010) Drugs and tinnitus: a review of a controversial matter. Audiol Med 8(1):1–4. doi:10.3109/16513861003647027 CrossRefGoogle Scholar
  12. 12.
    Han BI, Lee HW, Kim TY, Lim JS, Shin KS (2009) Tinnitus: characteristics, causes, mechanisms, and treatments. J Clin Neurol 5(1):11–19. doi:10.3988/jcn.2009.5.1.11 PubMedCrossRefGoogle Scholar
  13. 13.
    Bocci VA (2006) Scientific and medical aspects of ozone therapy. State of the art. Arch Med Res 37(4):425–435. doi:10.1016/j.arcmed.2005.08.006 PubMedCrossRefGoogle Scholar
  14. 14.
    Velio B (2005) OZONE—a new medical drug. Springer, Netherlands, 20:83Google Scholar
  15. 15.
    Bocci V, Zanardi I, Travagli V (2011) Oxygen/ozone as a medical gas mixture. A critical evaluation of the various methods clarifies positive and negative aspects. Med Gas Res 1(1):6. doi:10.1186/2045-9912-1-6 PubMedCrossRefGoogle Scholar
  16. 16.
    Pryor WA, Squadrito GL, Friedman M (1995) The cascade mechanism to explain ozone toxicity: the role of lipid ozonation products. Free Radic Biol Med 19(6):935–941. doi:10.1016/0891-5849(95)02033-7 PubMedCrossRefGoogle Scholar
  17. 17.
    Phillips JS, Prinsley PR (2008) Prescribing practices for Betahistine. Br J Clin Pharmacol 65(4):470–471PubMedCrossRefGoogle Scholar
  18. 18.
    Laurikainen E, Miller J, Nuttall A, Quirk W (1998) The vascular mechanism of action of betahistine in the inner ear of the guinea pig. Eur Arch Otorhinolaryngol 255(3):119–123PubMedCrossRefGoogle Scholar
  19. 19.
    Schmidt JT, Huizing EH (1992) The clinical drug trial in Menière’s disease with emphasis on the effect of betahistine SR. Acta Otolaryngol Suppl 497:1PubMedGoogle Scholar
  20. 20.
    Jakobs P, Martin G (1978) Springer HNO. The therapy of tinnitus resulting from blast injury. HNO 26:104–106PubMedGoogle Scholar
  21. 21.
    Ma F, Xin Y, Zhao Y, Lü J (2006) Efficacy of Betahistine Mesilate combined with Flunarizine Hydrochloride for treating tinnitus. Zhonghua er bi yan hou tou jing wai ke za zhi = Chin J Otorhinolaryngol Head Neck Surg 41 (4):269Google Scholar
  22. 22.
    James A, Burton MJ (2001) Betahistine for Ménière’s disease or syndrome. Cochrane Database Syst Rev (1):CD001873. doi:10.1002/14651858.CD001873
  23. 23.
    Akkuzu B, Yilmaz I, Cakmak O, Ozluoglu LN (2004) Efficacy of misoprostol in the treatment of tinnitus in patients with diabetes and/or hypertension. Auris Nasus Larynx 31(3):226–232PubMedCrossRefGoogle Scholar
  24. 24.
    Yilmaz I, Akkuzu B, Çakmak Ö, Özlüoglu LN (2004) Misoprostol in the treatment of tinnitus: a double-blind study. Otolaryngol Head Neck Surg 130(5):604PubMedCrossRefGoogle Scholar
  25. 25.
    Arda HN, Tuncel U, Akdogan O, Ozluoglu LN (2003) The role of zinc in the treatment of tinnitus. Otology Neurotol 24(1):86CrossRefGoogle Scholar
  26. 26.
    Rybak LP (2007) Vestibüler ve İşitsel Toksisite. In: Cummings CW (ed) Otolaringoloji Baş ve Boyun Cerrahisi, vol 4, 5th edn. Güneş Tıp Kitabevi, Ankara, pp 2933–2943Google Scholar
  27. 27.
    Jastreboff P, Gray W, Mattox D (1998) Tinnitus and hyperacusis. In: Cummings C, Frederickson J, Harker L et al (eds) Otolaryngology Head and Neck Surgery, 3rd edn. Mosby-Year Book, St. Louis, pp 3198–3222Google Scholar
  28. 28.
    Meikle MB, Stewart BJ, Griest SE, Henry JA (2008) Tinnitus outcomes assessment. Trends in Amplif 12(3):223–235CrossRefGoogle Scholar
  29. 29.
    Newman CW, Sandridge SA (2004) Tinnitus questionnaires. In: Snow JB (ed) Tinnitus: Theory and management. BC Decker Inc, Hamilton, pp 237–254Google Scholar
  30. 30.
    Henry JA, Meikle MB (2000) Psychoacoustic measures of tinnitus. J Am Acad Audiol 11(3):138PubMedGoogle Scholar
  31. 31.
    Tyler R (2000) Psychoacoustical measurement. Tinnitus Handbook. Singular Publishing Group, San Diego, pp 149–180Google Scholar
  32. 32.
    Hiller W, Goebel G (2006) Factors influencing tinnitus loudness and annoyance. Arch Otolaryngol Head Neck Surg 132(12):1323PubMedCrossRefGoogle Scholar
  33. 33.
    Giunta R, Coppola A, Luongo C, Sammartino A, Guastafierro S, Grassia A, Giunta L, Mascolo L, Tirelli A, Coppola L (2001) Ozonized autohemotransfusion improves hemorheological parameters and oxygen delivery to tissues in patients with peripheral occlusive arterial disease. Ann Hematol 80(12):745–748PubMedCrossRefGoogle Scholar
  34. 34.
    Romero A, Menéndez S, Gómez M, Ley J (1993) La ozonoterapia en los estadios avanzados de la aterosclerosis obliterante. Angiologia 45:146–148Google Scholar
  35. 35.
    Duplaa R, Planas G (1991) La ozonoterapia en el tratamiento de las úlceras crónicas de las extremidades inferiores. Angiologia 43Google Scholar
  36. 36.
    Bocci V (1996) Does ozone therapy normalize the cellular redox balance?: implications for the therapy of human immunodeficiency virus infection and several other diseases. Med Hypotheses 46(2):150–154PubMedCrossRefGoogle Scholar
  37. 37.
    Hernández F, Menendez S, Wong R (1995) Decrease of blood cholesterol and stimulation of antioxidative response in cardiopathy patients treated with endovenous ozone therapy. Free Radic Biol Med 19(1):115–119PubMedCrossRefGoogle Scholar
  38. 38.
    Leon O, Menéndez S, Merino N, Castillo R, Sam S, Pérez L, Cruz E, Bocci V (1998) Ozone oxidative preconditioning: a protection against cellular damage by free radicals. Mediat Inflamm 7:289–294CrossRefGoogle Scholar
  39. 39.
    Barber E, Menéndez S, Leon O, Barber M, Merino N, Calunga J, Cruz E, Bocci V (1999) Prevention of renal injury after induction of ozone tolerance in rats submitted to warm ischaemia. Mediat Inflamm 8(1):37–41CrossRefGoogle Scholar
  40. 40.
    Peralta C, Leon O, Xaus C, Prats N, Jalil E, Planell ES, Puig-Parellada P, Gelpi E, Rosello-Catafau J (1999) Protective effect of ozone treatment on the injury associated with hepatic ischemia-reperfusion: antioxidant-prooxidant balance. Free Radic Res 31(3):191–196PubMedCrossRefGoogle Scholar
  41. 41.
    Bocci V, Valacchi G, Corradeschi F, Aldinucci C, Silvestri S, Paccagnini E, Gerli R (1998) Studies on the biological effects of ozone: 7. Generation of reactive oxygen species (ROS) after exposure of human blood to ozone. J Biol Regul Homeost Agents 12(3):67PubMedGoogle Scholar
  42. 42.
    Coppola L, Giunta R, Verrazzo G, Luongo C, Sammartino A, Vicario C, Giugliano D (1995) Infuence of ozone on haemoglobin oxygen affinity in Type-2 diabetic patients with peripheral vascular disease: in vitro studies. Diabète et métabolisme 21(4):252–255PubMedGoogle Scholar
  43. 43.
    Kaźmierczak H, Pawlak-Osińska K, Kaźmierczak W (2004) Betahistine in vertebrobasilar insufficiency. Int Tinnitus J 10(2):191PubMedGoogle Scholar
  44. 44.
    Albera R, Ciuffolotti R, Di Cicco M, De Benedittis G, Grazioli I, Melzi G, Mira E, Pallestrini E, Passali D, Serra A (2003) Double-blind, randomized, multicenter study comparing the effect of betahistine and flunarizine on the dizziness handicap in patients with recurrent vestibular vertigo. Acta Oto Laryngol 123(5):588CrossRefGoogle Scholar
  45. 45.
    Suga F, Snow JB Jr (1969) Cochlear blood flow in response to vasodilating drugs and some related agents. Laryngoscope 79(11):1956–1979PubMedCrossRefGoogle Scholar
  46. 46.
    Rivera V, Meyer J, Baer P, Faibish G, Mathew N, Hartmann A (1974) Vertebrobasilar arterial insufficiency with dementia. Controlled trials of treatment with betahistine hydrochloride. J Am Geriatr Soc 22(9):397PubMedGoogle Scholar
  47. 47.
    Petrova D, Sachansca T, Datcov E (2004) Investigation of Betaserc in auditory and vestibular disturbances. Int Tinnitus J 10(2):177PubMedGoogle Scholar
  48. 48.
    Dobie RA (1999) A review of randomized clinical trials in tinnitus. Laryngoscope 109(8):1202–1211PubMedCrossRefGoogle Scholar
  49. 49.
    Pyykkö I, Zou J, Kentala E, Stephens D (2008) Tinnitus treatment: Are drugs effective? Audiol Med 6(1):25–39CrossRefGoogle Scholar
  50. 50.
    Nakashima T, Naganawa S, Sone M, Tominaga M, Hayashi H, Yamamoto H, Liu X, Nuttall AL (2003) Disorders of cochlear blood flow. Brain Res Rev 43(1):17–28PubMedCrossRefGoogle Scholar
  51. 51.
    Lamm K, Arnold W (1996) Noise-induced cochlear hypoxia is intensity dependent, correlates with hearing loss and precedes reduction of cochlear blood flow. Audiol Neurotol 1(3):148–160CrossRefGoogle Scholar
  52. 52.
    Lamm K, Arnold W (2000) The effect of blood flow promoting drugs on cochlear blood flow, perilymphatic pO2 and auditory function in the normal and noise-damaged hypoxic and ischemic guinea pig inner ear. Hear Res 141(1–2):199–219PubMedCrossRefGoogle Scholar
  53. 53.
    Bennett MH, Kertesz T, Yeung P (2007) Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss and tinnitus. Cochrane Database Syst Rev 24(1):CD004739Google Scholar
  54. 54.
    Elgoyhen AB, Langguth B (2010) Pharmacological approaches to the treatment of tinnitus. Drug Discov Today 15(7–8):300–305. doi:10.1016/j.drudis.2009.11.003 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Onur Sönmez
    • 1
  • İsmail Külahlı
    • 2
  • Alperen Vural
    • 2
    • 3
  • Mehmet İlhan Şahin
    • 2
  • Mesut Aydın
    • 2
  1. 1.Nevsehir Dr. I. Sevki Atasagun State HospitalNevsehirTurkey
  2. 2.Department of OtorhinolaryngologyErciyes University Faculty of MedicineKayseriTurkey
  3. 3.Erciyes Universitesi Kulak Burun Bogaz KlinigiKayseriTurkey

Personalised recommendations